- CEO
- Ling Feng Jiang
- Full Time Employees
- 6,292
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Building T1, IFS Chongqing CH China 400020
- IPO Date
- Sep 10, 2010
- Business
- Chongqing Zhifei Biological Products Co., Ltd. Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ) engages in the research, development, production, marketing, distribution, import, and export of vaccines and biological products primarily in China. Founded in 2002 and headquartered in Chongqing, the company operates through subsidiaries including Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., serving infants, adolescents, and adults with a focus on preventing infectious diseases such as meningitis, pneumonia, tuberculosis, influenza, rotavirus gastroenteritis, cervical cancer, and herpes zoster. Its core proprietary products encompass Group ACYW135 Meningococcal Polysaccharide Vaccine (Menwayc), Meningococcal Group A and C Conjugate Vaccine (Mening A Con), Haemophilus Influenzae Type b Conjugate Vaccine (XiFeiBei), AC Meningococcal Polysaccharide Vaccine (Mengnake), Recombinant Novel Coronavirus Vaccine (CHO Cell; Zifivax), Recombinant Mycobacterium Tuberculosis Fusion Protein (EC; Ekear), Mycobacterium Vaccae for Injection (Vaccae), and 23-valent Pneumococcal Polysaccharide Vaccine; as the exclusive distributor for imported vaccines, it offers Merck Sharp & Dohme products including four-valent and nine-valent Human Papillomavirus Vaccines (Gardasil and Gardasil 9), five-valent Rotavirus Vaccine (Rotateq), 23-valent Pneumococcal Vaccine (Pneumovax 23), and Hepatitis A Vaccine (Vaqta), alongside GlaxoSmithKline's Recombinant Zoster Vaccine (Shingrix). In December 2024, the company signed a supplementary agreement with GlaxoSmithKline to extend exclusive importation, distribution, and joint promotion rights for Shingrix in mainland China through 2034, with potential volumes valued at £2.3 billion to GlaxoSmithKline over 2024-2029 and exploration of collaboration on an RSV vaccine; earlier in 2024, MSD's HPV vaccines gained approval for male indications in China, enhancing herd immunity efforts, while proprietary products like the TB diagnostic Ekear joined the National Reimbursement Drug List and AC polysaccharide vaccine secured national procurement bids. The company maintains a "production determined by sales" model with nationwide direct sales via over 30,000 vaccination points, invests heavily in R&D (RMB 1.39 billion in 2024 across influenza, pneumococcal, meningococcal, and multivalent vaccines), and pursues international expansion including approvals in Indonesia and ongoing registrations in high-TB-burden countries.